[Current opportunities of pharmacotherapy of prostatic adenoma].
Apolikhin
O I
OI
Sivkov
A V
AV
Beshliev
D A
DA
Abdullin
I I
II
D058891:5-alpha Reductase Inhibitors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D011788:Quality of Life; D016896:Treatment Outcome
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists